The economic burden of heart conditions in Latin America | Deloitte Australia | Deloitte Access Economics reports, Life sciences and health care has been added to your bookmarks.
The economic burden of heart conditions in Latin America
Assessing the impact
This information was presented at ISPOR Vienna (1 November 2016) and the World Cardiovascular Congress (4-6 June 2016) on heart failure, myocardial infarction, atrial fibrillation, and hypertension in Latin America.
Heart conditions impose physical, social, financial, and health related quality of life limitations on individuals affected. These conditions result in an economic burden and impact on society due to expenditures on health care treatment, productivity losses from employment impacts, costs of providing formal and informal care, and lost wellbeing. The economic burden of heart conditions in the Latin American region has not been previously quantified.
This study assessed the economic burden of heart failure, myocardial infarction, atrial fibrillation, and hypertension in Brazil, Chile, Colombia, Ecuador, El Salvador, Mexico, Panama, Peru, and Venezuela. The cost effectiveness of structured telephone support and telemedicine for the treatment of heart failure was also assessed.
Total financial costs in the nine countries for the selected conditions in 2015 was estimated to be 30.9 billion USD.
- Health system costs took up 4.7% of all health spending, and productivity losses were the equivalent of 0.3% of the combined gross domestic product
- Myocardial infarction imposes the greatest financial cost (12.6 billion USD), followed by heart failure (10.7 billion USD), hypertension (5.3 billion USD) and, finally, atrial fibrillation (2.4 billion USD)
- Telemedicine and structured telephone support are cost effective mechanisms for achieving improvements in the management of heart failure.